Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 23:13:979873.
doi: 10.3389/fphar.2022.979873. eCollection 2022.

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305

Jingcao Zheng  1   2 , Zhengyu Li  1   2 , Wenjiao Min  3
Affiliations
Review

Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305

Jingcao Zheng et al. Front Pharmacol. .

Abstract

The family of poly (ADP-ribose) polymerases (PARPs) consists of 17 members, which have been demonstrated as having effects on a series of cellular processes, including DNA replication and repair. PARP inhibitors (PARPi) suppress DNA repair through "PARP trapping", thus, constitute an important treatment option for cancer nowadays. In addition, PARP inhibition and homologous recombination repair (HRR) defects are synthetically lethal, giving a promising therapeutic for homologous recombination repair deficient (HRD) tumors including BRCA mutation. However, overlapping hematologic toxicity causes PARPi to fail in combination with some first-line chemotherapies. Furthermore, recent literature has demonstrated that PARP1 inhibition and PARP1-DNA trapping are key for antitumor activity in HRD cancer models. Currently approved PARPi have shown varying levels of selectivity for the entire 17-member PARP family, hence contribute to toxicity. Together, these findings above have provided the necessity and feasibility of developing next-generation PARPi with improved selectivity for PARP1, expanding significant clinical values and wide application prospects both in monotherapy and combination with other anticancer agents. In this review, we summery the latest research of current approved PARPi, discuss the current status and future promise of next-generation PARP1-selective inhibitor AZD5305, including its reported progress up to now and anticipated impact on clinical.

Keywords: AZD5305; PARP inhibitors; improved selectivity; novel therapy; oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Audeh M. W., Carmichael J., Penson R. T., Friedlander M., Powell B., Bell-McGuinn K. M., et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 376, 245–251. 10.1016/s0140-6736(10)60893-8 - DOI - PubMed
    1. AZD5305 more tolerable than earlier PARP agents. Cancer Discov. 2022;12(7):1602. 10.1158/2159-8290.CD-NB2022-0039 - DOI - PubMed
    1. Balasubramaniam S., Beaver J. A., Horton S., Fernandes L. L., Tang S., Horne H. N., et al. (2017). FDA approval summary: Rucaparib for the treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer. Clin. Cancer Res. 23, 7165–7170. 10.1158/1078-0432.Ccr-17-1337 - DOI - PubMed
    1. Berek J. S., Matulonis U. A., Peen U., Ghatage P., Mahner S., Redondo A., et al. (2018). Safety and dose modification for patients receiving niraparib. Ann. Oncol. 29, 1784–1792. 10.1093/annonc/mdy181 - DOI - PubMed
    1. Boussios S., Rassy E., Shah S., Ioannidou E., Sheriff M., Pavlidis N. (2021). Aberrations of DNA repair pathways in prostate cancer: A cornerstone of precision oncology. Expert Opin. Ther. Targets 25, 329–333. 10.1080/14728222.2021.1951226 - DOI - PubMed